ライフサイエンスコーパス: community-acquired

1 64% were males, and nearly all influenza was community acquired.

2 ired [8 d] vs healthcare associated [3 d] vs community acquired [3 d]), and median hospital costs (ho

3 ents screened, 678 individuals with SAB (24% community acquired, 56% healthcare associated, and 20% n

4 red [17 d] vs healthcare associated [7 d] vs community acquired [6 d]), median length of ICU stay (ho

5 38,369] vs healthcare associated [$8,796] vs community acquired [$7,024]).

6 The Swedish quality registry for community-acquired ABM was analyzed retrospectively.

7 2337 (58%) patients developed community-acquired acute kidney injury, with 889 (80%) o

8 entation resulted in significant declines in community-acquired alveolar pneumonia (CAAP) and overall

9 We examined whether community-acquired alveolar pneumonia (CAAP) in children

10 Community-acquired alveolar pneumonia (CAAP) is consider

11 pes and respiratory viruses during childhood community-acquired alveolar pneumonia (CAAP).

12 l detection among children <5 years old with community-acquired alveolar pneumonia (CAAP; "cases") an

13 Both community-acquired and hospital-acquired cases have been

14 reus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection world

15 It is active towards community-acquired and hospital-associated MRSA strains

16 tes in children and adults, and against both community-acquired and household-acquired infections.

17 Norovirus is the leading cause of community-acquired and nosocomial acute gastroenteritis.

18 t species of this genus, known to cause both community-acquired and nosocomial infections worldwide.

19 ebsiella pneumoniae is an etiologic agent of community-acquired and nosocomial pneumonia.

20 The 30-day mortality in those with MDR community-acquired bacteraemia, healthcare-associated ba

21 with neither Pseudomonas aeruginosa nor non-community-acquired bacteria.

22 We analyzed episodes of community-acquired bacterial meningitis associated with

23 Of 2264 episodes of community-acquired bacterial meningitis between 2006 and

24 in a prospective nationwide cohort study of community-acquired bacterial meningitis.

25 New antibacterials are needed to treat community-acquired bacterial pneumonia (CABP) because of

26 Community-acquired bacterial pneumonia (CABP) is a leadi

27 Community-acquired bacterial pneumonia (CABP) remains a

28 remain in primary endpoints recommended for community-acquired bacterial pneumonia (CABP) trials.

29 is active against pathogens commonly causing community-acquired bacterial pneumonia (CABP).

30 A total of 863 adults with community-acquired bacterial pneumonia (Pneumonia Outcom

31 ndomly assigned (in a 1:1 ratio) adults with community-acquired bacterial pneumonia (Pneumonia Severi

32 and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacteri

33 dpoints in registrational clinical trials of community-acquired bacterial pneumonia and acute bacteri

34 nferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults.

35 erial skin and skin structure infections and community-acquired bacterial pneumonia in adults.

36 ermine whether a drug should be approved for community-acquired bacterial pneumonia in the United Sta

37 s active against common pathogens that cause community-acquired bacterial pneumonia.

38 ted 2 global phase 3 trials for treatment of community-acquired bacterial pneumonia.

39 ravenous and oral option for monotherapy for community-acquired bacterial pneumonia.

40 rved in the phase III study in patients with community-acquired bacterial pneumonia.

41 erial skin and skin structure infections and community-acquired bacterial pneumonia.

42 erial skin and skin structure infections and community-acquired bacterial pneumonia.

43 n isolates in a large panel of hospital- and community-acquired Bacteroides.

44 Salmonella enterica is a leading cause of community-acquired bloodstream infection in Africa.

45 Community-acquired bloodstream infections cause substant

46 almonella (NTS) are the predominant cause of community-acquired bloodstream infections in sub-Saharan

47 Community-acquired (CA) bacteremia with same species was

48 Community-acquired (CA) sepsis is a major public health

49 Changes in community-acquired (CA)-ARO, CA-MDRO, and inpatient AMU

50 Changes in community-acquired (CA-) ARO, CA-MDRO, and inpatient AMU

51 hips between some hospital-acquired and some community-acquired cases.

52 For patients with community-acquired cholangitis without biliary prosthesi

53 potential emerging pathogen associated with community-acquired gastroenteritis and traveler's diarrh

54 ses were all children ages 0.5-17 years with community acquired, gram-negative quinolone resistant ba

55 ses were all children aged 0.5-17 years with community acquired, gram-negative quinolone-resistant ba

56 orally associated samples from patients with community-acquired HPIV3 were analyzed.

57 criteria through sepsis, the infections were community acquired in 48.5% and hospital acquired in 51.

58 rall prevalence and outpatient and inpatient community-acquired incidence followed a seasonal pattern

59 Melioidosis is an important cause of community-acquired infection in Southeast Asia and north

60 , concurrent InfA strains from patients with community-acquired infection were included.

61 th Pneumocystis by cohabitation, to resemble community-acquired infection, underwent lung assessments

62 us is a leading cause of both nosocomial and community-acquired infection.

63 nce of nosocomial transmission compared with community-acquired infection?

64 ains have spread throughout hospitals, while community acquired infections and other sources ensure a

65 with shorter times to antimicrobial therapy: community-acquired infections (-53 min; p < 0.001) and h

66 Community-acquired infections (CAIs) were cultures posit

67 A parallel phenomenon of severe community-acquired infections caused by 'hypervirulent'

68 he magnitude and term of morbidity of acute, community-acquired infections in immune competent patien

69 ntibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Ca

70 reas in the smaller group of inpatients with community-acquired infections, 12 capsid and 9 polymeras

71 Of the bacteria typically responsible for community-acquired infections, clarithromycin-resistant

72 has an appropriate spectrum of activity for community-acquired infections, including those caused by

73 timicrobial resistance, especially regarding community-acquired infections.

74 the etiological agent of many hospital- and community-acquired infections.

75 ial resistance in both hospital-acquired and community-acquired infections.

76 us is now one of the key causative agents of community-acquired infections.

77 hypervirulent strains associated with severe community-acquired infections.

78 human pathogen causing hospital-acquired and community-acquired infections.

79 auses toxin-mediated nosocomial diarrhea and community-acquired infections; no preventive vaccine is

80 esity were associated with increased risk of community-acquired infectious diseases, especially infec

81 Using two community-acquired influenza cohorts, we showed that the

82 e prevalence and incidence of outpatient and community-acquired inpatient norovirus AGE at 4 Veterans

83 d before lumbar puncture (LP) in adults with community-acquired meningitis (CAM).

84 ococcus aureus, especially highly pathogenic community-acquired methicillin-resistant S aureus strain

85 The recent spread of community-acquired methicillin-resistant Staphylococcus

86 In the United States, an epidemic of community-acquired methicillin-resistant Staphylococcus

87 of various antibiotic regimens in the era of community-acquired methicillin-resistant Staphylococcus

88 ence of antibiotic-resistant strains such as community-acquired methicillin-resistant Staphylococcus

89 xpansion of staphylococcal disease caused by community-acquired methicillin-resistant Staphylococcus

90 a pandemic clonal lineage of hypervirulent, community-acquired, methicillin-resistant Staphylococcus

91 ce and incidence of outpatient and inpatient community-acquired norovirus in US Veterans, highlightin

92 peak prevalence and outpatient and inpatient community-acquired norovirus incidence rates in the firs

93 notypes among inpatients with nosocomial and community-acquired NoV infections, respectively.

94 d factors and causes hospital infections and community-acquired ocular infections.

95 cohort study of adult patients admitted with community-acquired or healthcare-associated pneumonia to

96 cohort study of adult patients admitted with community-acquired or healthcare-associated pneumonia to

97 Knowledge of whether pneumonia is community-acquired or nosocomial, as well as the age and

98 Knowledge of whether pneumonia is community-acquired or nosocomial, as well as the age and

99 moniae (hvKp) is globally disseminating as a community-acquired pathogen causing life-threatening inf

100 occus aureus (MRSA) is a major hospital- and community-acquired pathogen, but the mechanisms underlyi

101 performed a genetic association study in 469 community-acquired pneumococcal meningitis cases and 207

102 ographics and comorbidities of patients with community acquired pneumonia (CAP) vary enormously but s

103 Coccidioidomycosis (CM) is a common cause of community acquired pneumonia (CAP) where CM is endemic.

104 ociated with a poor outcome in patients with community acquired pneumonia (CAP).

105 spitalisations for non-invasive pneumococcal community acquired pneumonia (PnCAP) to evaluate long-te

106 ted to the intensive care unit due to severe community acquired pneumonia.

107 PIV serotypes in patients hospitalized with community acquired pneumonia.

108 d ratio, 1.21; 95% CI, 1.06-1.36) and severe community-acquired pneumonia (adjusted hazard ratio, 1.5

109 them to a cohort of patients with bacterial community-acquired pneumonia (B-CAP).

110 Mycoplasma pneumoniae is a leading cause of community-acquired pneumonia (CAP) across patient popula

111 Community-acquired pneumonia (CAP) and acute exacerbatio

112 en aged <18 years who were hospitalized with community-acquired pneumonia (CAP) and children asymptom

113 Prevalence of Staphylococcus aureus community-acquired pneumonia (CAP) and its clinical feat

114 lected urine from hospitalized patients with community-acquired pneumonia (CAP) and performed a compr

115 , rs1800451, and rs7096206) in 1839 European community-acquired pneumonia (CAP) and peritonitis sepsi

116 Because of the diverse etiologies of community-acquired pneumonia (CAP) and the limitations o

117 of pneumonia, causing about 15-20% of adult community-acquired pneumonia (CAP) and up to 40% of case

118 ggest that statins may benefit patients with community-acquired pneumonia (CAP) due to antiinflammato

119 iate Mycoplasma pneumoniae (Mp) infection in community-acquired pneumonia (CAP) from other etiologies

120 availability, but hospitalized patients with community-acquired pneumonia (CAP) generally are treated

121 Adult, community-acquired pneumonia (CAP) guidelines from the I

122 nfectious Diseases Society of America (IDSA) Community-acquired Pneumonia (CAP) guidelines were devel

123 In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in

124 quent lack of a microbiological diagnosis in community-acquired pneumonia (CAP) impairs pathogen-dire

125 data describing the etiology and outcome of community-acquired pneumonia (CAP) in sub-Saharan Africa

126 Inhaled corticosteroids (ICS) increase community-acquired pneumonia (CAP) incidence in patients

127 Community-acquired pneumonia (CAP) is a leading cause of

128 treatment for additional potential causes of community-acquired pneumonia (CAP) is appropriate.

129 Previous reports suggest that community-acquired pneumonia (CAP) is associated with an

130 Community-acquired pneumonia (CAP) is common and often s

131 Understanding the burden of community-acquired pneumonia (CAP) is critical to alloca

132 Information on the long-term prognosis after community-acquired pneumonia (CAP) is limited.

133 ficance of viruses detected in patients with community-acquired pneumonia (CAP) is often unclear.

134 Although community-acquired pneumonia (CAP) is one of the most co

135 ng US children (<18 years) hospitalized with community-acquired pneumonia (CAP) is poorly understood.

136 Among immunocompromised patients, community-acquired pneumonia (CAP) pathogens were the mo

137 is is a prospective longitudinal study of 63 community-acquired pneumonia (CAP) patients and 21 healt

138 The effect of body mass index (BMI) on community-acquired pneumonia (CAP) severity is unclear.

139 ults with low pGSN at hospital admission for community-acquired pneumonia (CAP) were at high risk for

140 tment for patients with clinically suspected community-acquired pneumonia (CAP) who are admitted to n

141 t had culture-positive tuberculosis, 100 had community-acquired pneumonia (CAP), 26 had P. jirovecii

142 k of invasive pneumococcal disease (IPD) and community-acquired pneumonia (CAP), it is unclear whethe

143 of pure viral sepsis in adult patients with community-acquired pneumonia (CAP), using the Sepsis-3 d

144 ostic indicator in persons hospitalized with community-acquired pneumonia (CAP).

145 gen detection for patients hospitalized with community-acquired pneumonia (CAP).

146 used previously to determine the etiology of community-acquired pneumonia (CAP).

147 -acquired pneumonia (HAP) when compared with community-acquired pneumonia (CAP).

148 g cause of respiratory infections, including community-acquired pneumonia (CAP).

149 onia in a cohort of adults hospitalised with community-acquired pneumonia (CAP).

150 o evaluate the epidemiology of nonbacteremic community-acquired pneumonia (CAP).

151 pneumococcal disease (IPD) and pneumococcal community-acquired pneumonia (CAP).

152 sepsis due to fecal peritonitis (n = 117) or community-acquired pneumonia (n = 126), and of control s

153 ute respiratory distress syndrome induced by community-acquired pneumonia (n=10), CXCR1 and CXCR2 exp

154 88; n = 921 participants), and S. pneumoniae community-acquired pneumonia (OR = 2.15; 95% CI = 1.32-3

155 ospitalizations for noninvasive pneumococcal community-acquired pneumonia (PnCAP) to evaluate long-te

156 Postobstructive community-acquired pneumonia (PO-CAP) is relatively comm

157 Incidence estimates of hospitalizations for community-acquired pneumonia among children in the Unite

158 ospitals involving patients with both severe community-acquired pneumonia and a high inflammatory res

159 gionella are recognised as a common cause of community-acquired pneumonia and a rare cause of hospita

160 We describe severe community-acquired pneumonia and bacteremia caused by He

161 to those provided by etiological studies of community-acquired pneumonia and emphasize the potential

162 o UK intensive care units with sepsis due to community-acquired pneumonia and evidence of organ dysfu

163 Among patients with severe community-acquired pneumonia and high initial inflammato

164 ntigen detection assay were used to identify community-acquired pneumonia and invasive pneumococcal d

165 e (the pneumococcus) is the leading cause of community-acquired pneumonia and is now recognized to be

166 ptococcus pneumoniae is the leading cause of community-acquired pneumonia and sepsis, with adult hosp

167 Streptococcus pneumoniaeis a major cause of community-acquired pneumonia and septicemia in adults.

168 pneumococcal, bacteremic, and nonbacteremic community-acquired pneumonia and vaccine-type invasive p

169 ving extracorporeal membrane oxygenation for community-acquired pneumonia between 2002 and 2012.

170 The clinical course of complicated community-acquired pneumonia can be prolonged, especiall

171 gnosed diabetes mellitus in a large European community-acquired pneumonia cohort.

172 ty-acquired pneumonia included in the German Community-Acquired Pneumonia Competence Network (CAPNETZ

173 al multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010

174 Community-acquired pneumonia deaths (n = 32) were attrib

175 vasive pneumococcal disease and pneumococcal community-acquired pneumonia differed by age and between

176 e pneumococcal disease but not in preventing community-acquired pneumonia from any cause.

177 a cohort study including adult patients with community-acquired pneumonia from two Spanish university

178 2 group than in the influenza group and the community-acquired pneumonia group (1.91 vs 1.48 vs 1.53

179 surveillance for radiographically confirmed community-acquired pneumonia hospitalizations among chil

180 nter, prospective, population-based study of community-acquired pneumonia hospitalizations conducted

181 In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adult

182 Complicated community-acquired pneumonia in a previously well child

183 nts, but their efficacy against pneumococcal community-acquired pneumonia in adults 65 years of age o

184 CV13) against first episodes of vaccine-type community-acquired pneumonia in adults aged >/=65 years

185 Data on outcomes from severe community-acquired pneumonia in adults receiving rescue

186 Coccidioidomycosis is a common cause of community-acquired pneumonia in areas of the southwester

187 Child Health (PERCH) study, a large study of community-acquired pneumonia in children aged 1-59 month

188 pneumoniae is the leading cause of bacterial community-acquired pneumonia in persons of all ages.

189 olipid lysoPCaC26:1 identified patients with community-acquired pneumonia in sepsis or severe sepsis/

190 butes to the pathogenesis of childhood acute community-acquired pneumonia in settings with a high tub

191 usefulness as prompt tools for patients with community-acquired pneumonia in the emergency department

192 d workers and 1% in healthcare workers); and community-acquired pneumonia in working-age adults (PAF,

193 ny and Austria encompassing 1961 adults with community-acquired pneumonia included in the German Comm

194 Community-acquired pneumonia is a leading infectious cau

195 Community-acquired pneumonia is commonly caused by Strep

196 es mellitus and prediabetes in patients with community-acquired pneumonia is largely unknown.

197 Streptococcus pneumoniae is a major cause of community-acquired pneumonia leading to high mortality r

198 21.8 to 62.5), nonbacteremic and noninvasive community-acquired pneumonia occurred in 33 persons in t

199 s of infections due to vaccine-type strains, community-acquired pneumonia occurred in 49 persons in t

200 37.7%, 41.1%, and 75.8%, respectively), and community-acquired pneumonia occurred in 747 persons in

201 ically ill patients such as sepsis or severe community-acquired pneumonia patients.

202 hospitalized with radiographically confirmed community-acquired pneumonia published from January 1, 1

203 omised patients and healthy individuals with community-acquired pneumonia remains an unmet medical ne

204 is a recommended treatment for patients with community-acquired pneumonia requiring hospital admissio

205 ted active population-based surveillance for community-acquired pneumonia requiring hospitalization a

206 lculated population-based incidence rates of community-acquired pneumonia requiring hospitalization a

207 ted active population-based surveillance for community-acquired pneumonia requiring hospitalization a

208 The incidence of community-acquired pneumonia requiring hospitalization w

209 VID(ICU) patients), and patients with severe community-acquired pneumonia requiring ICU support (CAP(

210 Complicated community-acquired pneumonia should be suspected in any

211 The majority (66%) of adults with community-acquired pneumonia supported on extracorporeal

212 a pathogenic bacterium and a major cause of community-acquired pneumonia that could be fatal if left

213 ts) and patients admitted with sepsis due to community-acquired pneumonia to 29 ICUs in the UK (secon

214 y and Infectious Diseases Society of America community-acquired pneumonia treatment guidelines.

215 4.7%, 78.2%, 75%, and 87%, respectively, for community-acquired pneumonia validated against a blinded

216 burden of hospitalization for children with community-acquired pneumonia was highest among the very

217 Research Team (PORT) risk class III-IV acute community-acquired pneumonia were randomly assigned (1:1

218 tolerated in hospitalized older adults with community-acquired pneumonia with sepsis (CAP + S) not a

219 occus pneumoniae is the most common cause of community-acquired pneumonia worldwide, and interleukin-

220 occus pneumoniae is the most common cause of community-acquired pneumonia worldwide.

221 dromes (including bloodstream infections and community-acquired pneumonia) in children and neonates (

222 emic inflammatory response syndrome, 100 for community-acquired pneumonia, 112 for urinary tract infe

223 for trauma; 15.0% vs 25.4%, p = 4.4 x 10 for community-acquired pneumonia, and 7.1% vs 20.0%, p = 3.4

224 , nonbacteremic and noninvasive pneumococcal community-acquired pneumonia, and invasive pneumococcal

225 during a lower respiratory tract infection, community-acquired pneumonia, and pneumonia associated w

226 In adults hospitalized with community-acquired pneumonia, antibiotic therapy consist

227 IPD and the most resource-intensive type of community-acquired pneumonia, hospital-treated pneumonia

228 other infections such as bacterial or viral community-acquired pneumonia, influenza, and tuberculosi

229 1 are associated with unfavorable outcome in community-acquired pneumonia, intra-abdominal infections

230 ccus pneumoniae, the most common pathogen of community-acquired pneumonia, led to exclusive damage in

231 odes of vaccine-type strains of pneumococcal community-acquired pneumonia, nonbacteremic and noninvas

232 gh-risk antibiotic in the prior 90 days, had community-acquired pneumonia, or did not have a total an

233 Among children and adults hospitalized with community-acquired pneumonia, those with laboratory-conf

234 ed in AMs from patients at increased risk of community-acquired pneumonia, to address the requirement

235 In patients with severe community-acquired pneumonia, treatment failure is assoc

236 tes mellitus is an important risk factor for community-acquired pneumonia, whereas the prevalence of

237 een PIV and other pathogens in patients with community-acquired pneumonia.

238 Mycoplasma pneumoniae is a major cause of community-acquired pneumonia.

239 ors for poor outcomes in adult patients with community-acquired pneumonia.

240 m monotherapy for children hospitalized with community-acquired pneumonia.

241 to compare these with the same parameters in community-acquired pneumonia.

242 gnosed diabetes mellitus was prevalent among community-acquired pneumonia.

243 ged 1-59 months enrolled in a large study of community-acquired pneumonia.

244 rveillance study of adults hospitalized with community-acquired pneumonia.

245 making analysis of Sepsis-3 in patients with community-acquired pneumonia.

246 ing acute respiratory disease (ARD), such as community-acquired pneumonia.

247 is the cornerstone of medical management for community-acquired pneumonia.

248 iae is the most common causative pathogen in community-acquired pneumonia.

249 ute respiratory distress syndrome induced by community-acquired pneumonia.

250 treatment of Asian patients with PORT III-IV community-acquired pneumonia.

251 ute respiratory distress syndrome induced by community-acquired pneumonia.

252 as patients admitted due to sepsis or severe community-acquired pneumonia.

253 isolates resistant to first-line therapy for community-acquired pneumonia.

254 care unit (ICU) patients with sepsis due to community-acquired pneumonia.

255 treatment strategies for adult patients with community-acquired pneumonia.

256 nes on the management of adult patients with community-acquired pneumonia.Methods: A multidisciplinar

257 siella pneumoniae strain, NTUH-K2044, from a community-acquired pyogenic liver abscess (PLA) patient.

258 n to mothers was linked to increased risk of community-acquired quinolone-resistant bacteria in their

259 n to mothers was linked to increased risk of community-acquired, quinolone-resistant bacteria in thei

260 DP-ribosylating and vacuolating toxin called community-acquired respiratory distress syndrome (CARDS)

261 e (mART) and vacuolating activities known as Community-Acquired Respiratory Distress Syndrome Toxin (

262 infections, and Chlamydia pneumoniae causes community-acquired respiratory infections.

263 Community-acquired respiratory virus (CARV) infections o

264 The relationship between community-acquired respiratory viruses (CARVs) and chron

265 nd reached Europe by late January 2020, when community-acquired respiratory viruses (CARVs) are at th

266 rea worthy of focus is the interface between community-acquired respiratory viruses and the respirato

267 Despite the dominant role of community-acquired respiratory viruses as etiological ag

268 dren aged younger than 5 years who died with community-acquired RSV infection between Jan 1, 1995, an

269 large case series of children who died with community-acquired RSV infection.

270 out significant illness after infection with community-acquired RSV.

271 A postvaccination decrease in hospitalized community-acquired RV infections by 89.3% was seen in al

272 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) ha

273 tion of patients with IE was 22% (36/166) in community-acquired SAB, 11% (40/378) in community-onset

274 l emergency medical services encounters with community acquired sepsis transported to the hospital.

275 f the study was to estimate the incidence of community-acquired sepsis based on patients' symptoms an

276 confidence interval [CI] 1.7-2.4) and 25% of community-acquired sepsis episodes.

277 The adjusted risk of community-acquired sepsis was higher for each lower cate

278 ong 58,934 prehospital encounters, 2,683 had community-acquired sepsis, with an in-hospital mortality

279 ital mortality among patient encounters with community-acquired sepsis.

280 are associated with in-hospital mortality in community-acquired sepsis.

281 ll gene expression patterns from humans with community-acquired sepsis.

282 of life morbidity for children encountering community-acquired septic shock.

283 f life morbidity among children encountering community-acquired septic shock.

284 to consecutive critically ill patients with community-acquired severe acute respiratory infection of

285 ies, severe sepsis hospitalizations included community-acquired severe sepsis (62.8%), healthcare-ass

286 gher mortality and resource utilization than community-acquired severe sepsis and healthcare-associat

287 pidemiologic studies have not differentiated community-acquired severe sepsis from healthcare-associa

288 Prevalence of community-acquired severe sepsis, healthcare-associated

289 We sought to compare and contrast community-acquired severe sepsis, healthcare-associated

290 both healthcare-associated severe sepsis and community-acquired severe sepsis, with higher median len

291 d for patients with and without asplenia and community-acquired severe sepsis/septic shock.

292 Twelve cases of community-acquired slowly or nonresolving LD were identi

293 as isolates obtained from or associated with community-acquired sources of Legionnaires' disease.

294 We assessed the association of Community acquired Staphylococcus aureus bloodstream inf

295 rea to determine the nature (clonal type) of community-acquired Staphylococcus aureus strains causing

296 ethoprim-sulfamethoxazole, and ampicillin in community-acquired urinary E. coli isolates in Montreal,

297 cherichia coli, a common agent of sepsis and community-acquired urinary tract infections, obtained du

298 hould focus on differentiating resistance in community-acquired versus hospital-acquired infections,

299 ity, pathogen, and pneumonia classification [community-acquired vs. health care-associated]) from the

300 ) infections are still frequently treated as community-acquired with a detrimental effect on survival